Anlon's capex quadrupled and CDMO timelines slipped. The explanations don't match.
Management said in November 2025 it had ₹31 cr saved for expansion and no need for debt. Now it's a ₹130 cr project with a ₹65-70 cr loan and delayed commercialization.
What's new
- Rajkot capex estimate jumped from ₹31 cr (Nov 2025) to ₹130 cr, now requiring a ₹65-70 cr bank loan.
- CDMO commercialization for two of three molecules pushed to Q4 FY27 or Q1 FY28 from a prior Q3 FY27 target.
- FY26 revenue grew 43% to ₹172.22 cr; EBITDA margin was 27.7%.
- FY27 revenue guidance set at ₹380-400 cr, with ₹280-300 cr order book already in hand.
Themes from the call
Capex & Funding
The greenfield expansion's cost and funding plan have fundamentally changed since the November 2025 call, moving from a fully-funded, debt-free plan to a leveraged one.
Credibility
The contradictory statements on both capex funding and CDMO timelines in two consecutive calls raise questions about the reliability of management's forward guidance.
Growth
FY26 showed strong organic and inorganic growth, and the ₹280-300 cr order book provides solid visibility for the bulk of FY27 revenue.
Margins
Management is navigating raw material inflation and acquisition drag, with a stated commitment to hold EBITDA margins at 25-30% despite integrated entity blending.
Guidance watch
- FY27 revenue guidance of ₹380-400 cr is backed by a ₹280-300 cr order book (74-79% of target).
- FY28 targets ₹700-800 cr as the Rajkot facility comes online.
- Management reaffirmed a three-year 30% revenue CAGR through FY29 while maintaining 25-30% EBITDA margins.
- CDMO Molecule 1 commercial supply still targeted for Q3 FY27; Molecules 2-3 commercialization now Q4 FY27 or Q1 FY28.
Risk flags
- The ₹31 cr to ₹130 cr capex swing and shift to debt financing without clear explanation undermines confidence in project budgeting.
- The CDMO timeline slip is a direct contradiction of prior guidance and delays the entry into a higher-margin business segment.
- A distributor default left ₹17 cr outstanding, and management has a strict new payment enforcement policy (halt supply at 120 days).
- FY26 operating cash flow was negative ₹47 cr due to inventory build and capex advances.
Key quotes
-
"...we have reserved the 31 CR for the new capex expansion... right now we don't need to get any debt or bank loan."
— Anlon Healthcare management, Nov 2025 call -
"The capex is expected to be around 130 crores... we are planning to obtain a term loan... for approximately 65 to 70 crores."
— Anlon Healthcare management, Jun 2026 call -
"Validation is already completed... We are expecting by third quarter of next year."
— Anlon Healthcare management, Nov 2025 call (on all 3 CDMO molecules) -
"For the other two molecules, validation is expected by Q2 FY27. We expect commercialization by Q4 FY27 or from Q1 FY28."
— Anlon Healthcare management, Jun 2026 call
The brief
Anlon Healthcare's June call contains two material contradictions with its November 2025 guidance. The more damaging concerns money: a ₹31 cr, debt-free expansion plan became a ₹130 cr project requiring a ₹65-70 cr bank loan. The second is about time: validation for two key CDMO molecules is no longer 'already completed' but is expected by Q2 FY27, pushing commercialization into the next financial year.
Management did not offer a clear bridge for either reversal. The capex change suggests the original scope was severely underestimated or the initial ₹31 cr was for a different phase. The CDMO delay appears more straightforwardly operational—validation work is taking longer than communicated in November.
The operational backdrop is otherwise strong. FY26 revenue grew 43% to ₹172.22 cr and the ₹280-300 cr order book covers 74-79% of the ₹380-400 cr FY27 target. Utilization at acquired facilities is 62-65% with room to 80%. The business itself is executing.
But the disconnect between what was told to investors in November and what is being said now is a problem. It forces a readjustment of trust in forward estimates. The Rajkot facility remains a Q1 FY28 commissioning target, but the budget and funding for it are now on different terms. The CDMO pipeline, a key part of the path to higher EBITDA, is later than promised. For a company pitching a three-year 30% CAGR, the foundation of that pitch just got shakier.
The numbers are growing, but management's past words aren't matching its present ones.